Gynecologic Cancer
From the Journals
In and out surgeries become the norm during pandemic
The number of same-day discharges has grown for various surgeries but it’s not always the right or the preferred choice, experts say.
From the Journals
Antibiotic and glucocorticoid use before cancer therapy could have detrimental effect on outcomes
Observational study finds that antibiotics and glucocorticoids at 10 mg daily when given within 1 month before or after immune checkpoint...
Conference Coverage
Cervical cancer mortality stagnates despite screening
Greater effort is needed to identify women who develop cervical cancer and diversify clinical trials.
Feature
Convenience, not outcomes may drive robot-assisted surgeries
The sale of robotically assisted surgical devices is expected to reach $14 billion by 2028. The technology is enticing to both surgeons and...
From the Journals
Early mortality falls in advanced ovarian cancer with neoadjuvant chemo
This observational study shows reductions in early mortality for patients with advanced ovarian cancer. The findings may inform treatment...
Latest News
Unexpected thrombocytosis could flag occult cancer
The risk was highest (23.3 times) for ovarian cancer. The risk was 3.8 times higher for pancreatic cancer and 3.5 times higher for cervical cancer...
Conference Coverage
Many patients, doctors unaware of advancements in cancer care
“These patients must be spared the traumatic effects of being handed a death sentence that no longer reflects the current reality,” said Dr....
Latest News
FDA approval for tisotumab vedotin in advanced cervical cancer
The mainstay of therapy in this setting is monotherapy with chemotherapy, but the benefit-risk profiles are poor, and overall response rates are...
Opinion
Management of advanced endometrial cancer
Arguably more important than surgical interventions, access to molecularly targeted systemic therapy is likely to bring the best outcomes for...
Conference Coverage
Most community-based oncologists skip biomarker testing
Survey shows that 48% of community clinicians use biomarker testing to guide treatment decisions, compared with 73% of academic clinicians.
From the Journals
Immunotherapy for cancer patients with poor PS needs a rethink
Patients should not receive immunotherapy just to reduce risk of side effects, doctor says.